The FY2025 (Dec) proxy of Tarsus Pharmaceuticals names 16 peer companies for pay. Among Tarsus Pharmaceuticals and these peers, CEO pay was the lowest of 5 and total shareholder return was 2nd highest of 5.
5th highest of 5in Tarsus Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
$6.6M$35.9M
2nd highest of 5in Tarsus Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
$59$495
Pay peer group, FY2025 (Dec) proxy
| Ocular Therapeutix | ||
| Supernus Pharmaceuticals | ||
| Mirum Pharmaceuticals | ||
| Arcutis Biotherapeutics | ||
| Ardelyx, Inc. | Not disclosed | Not disclosed |
| Aurinia Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Catalyst Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Day One Biopharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Dynavax Technologies Corp. | Not disclosed | Not disclosed |
| Evolus, Inc. | Not disclosed | Not disclosed |
| Harrow, Inc. | Not disclosed | Not disclosed |
| Ironwood Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Kiniksa Pharmaceuticals, Ltd. | Not disclosed | Not disclosed |
| Mannkind | Not disclosed | Not disclosed |
| Rhythm Pharmaceuticals | Not disclosed | Not disclosed |
| SpringWorks Therapeutics, Inc. | Not disclosed | Not disclosed |
16 companies
Changes by year
No proxy on file names a change to the peer group.
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.